Cellectis (CLLS) Stock Forecast, Price & News

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Cellectis in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" CLLS shares.
View CLLS analyst ratings or view top-rated stocks.

4 brokerages have issued 1 year price objectives for Cellectis' stock. Their CLLS share price forecasts range from $6.00 to $16.00. On average, they expect the company's stock price to reach $9.75 in the next year. This suggests a possible upside of 501.9% from the stock's current price.
View analysts price targets for CLLS or view top-rated stocks among Wall Street analysts.

Cellectis' stock was trading at $2.10 on January 1st, 2023. Since then, CLLS stock has decreased by 22.9% and is now trading at $1.62.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023.
View our CLLS earnings forecast.

Cellectis S.A. (NASDAQ:CLLS) released its quarterly earnings results on Thursday, August, 3rd. The biotechnology company reported ($0.14) EPS for the quarter, topping analysts' consensus estimates of ($0.38) by $0.24. The biotechnology company earned $2 million during the quarter, compared to analysts' expectations of $7.80 million. Cellectis had a negative trailing twelve-month return on equity of 71.63% and a negative net margin of 387.07%.

13 employees have rated Cellectis Chief Executive Officer André Choulika on Glassdoor.com. André Choulika has an approval rating of 100% among the company's employees. This puts André Choulika in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 39.0% of employees surveyed would recommend working at Cellectis to a friend.

Based on aggregate information from My MarketBeat watchlists, some companies that other Cellectis investors own include Gilead Sciences (gild), Calyxt (CLXT), NVIDIA (NVDA), AbbVie (ABBV), Micron Technology (MU), Advanced Micro Devices (AMD), CRISPR Therapeutics (CRSP), Editas Medicine (EDIT), Intel (INTC) and Sorrento Therapeutics (SRNE).

(CLLS) raised $129 million in an initial public offering (IPO) on Wednesday, March 25th 2015. The company issued 3,500,000 shares at $36.83 per share. BofA Merrill Lynch, Jefferies and Piper Jaffray served as the underwriters for the IPO and Oppenheimer was co-manager.

Cellectis trades on the NASDAQ under the ticker symbol "CLLS."

Cellectis' stock is owned by a variety of retail and institutional investors. Top institutional investors include Baillie Gifford & Co. (2.55%), Principal Financial Group Inc. (1.20%), Envestnet Asset Management Inc. (0.05%) and Citadel Advisors LLC (0.00%).

Shares of CLLS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of CLLS stock can currently be purchased for approximately $1.62.

Cellectis (NASDAQ:CLLS) has a market capitalization of $90.04 million and generates $25.73 million in revenue each year. The biotechnology company earns $-106,140,000.00 in net income (profit) each year or ($1.99) on an earnings per share basis.

The company employs 231 workers across the globe.

Cellectis' mailing address is 8 RUE DE LA CROIX JARRY, PARIS I0, 75013. The official website for the company is www.cellectis.com. The biotechnology company can be reached via phone at (318) 169-1600, via email at investors@cellectis.com, or via fax at 33-1-81-69-16-06.